Advertisement
Advertisement

GKOS

GKOS logo

Glaukos Corporation

130.14
USD
Sponsored
+3.33
+2.63%
Jun 15, 15:59 UTC -4
Closed
exchange

Pre-Market

133.99

+3.85
+2.96%

Glaukos Corporation Profile

About

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.

Info & Links

CEO

Thomas W. Burns

Headquarters

1 GLAUKOS WAY
ALISO VIEJO, CA 92656, UNITED STATES

Industry

Medical Instruments

Sector

Medical

Website

www.glaukos.com

Auditor

Ernst & Young LLP

Share holders

42

Employees

1,094

Glaukos Corporation Statistics

Valuation Measures

Market Capitalization2

7.87B

Enterprise Value

7.83B

Enterprise Value/EBITDA(ttm)

-50.58

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

13.67

Price to Book(mrq)

10.46

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

77.94%

Operating Margin(ttm)

-10.20%

Profit Margin(ttm)

-34.60%

Return on Equity(ttm)

-7.00%

Return on Invested Capital(ttm)

-24.93%

Return on Assets(ttm)

-5.38%

Income Statement

Revenue(ttm)

551.35M

Revenue Per Share(ttm)

9.39

Gross Profit(ttm)

430.51M

EBITDA(ttm)3

-154.88M

Net Income Available to Common(ttm)

-189.33M

Diluted EPS(ttm)

-3.26

Share Statistics

Beta (5Y Monthly)

0.78

52-Week Change

33.34%

S&P 500 52-Week Change

25.21%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

58.73M

Dividend Yield

0.00%

Float4

54.71M

% Held by Insiders

5.80%

% Held by Institutions

99.04%

Balance Sheet

Total Cash(mrq)

276.69M

Total Cash Per Share(mrq)

4.71

Total Debt(mrq)

67.74M

Total Debt/Equity(mrq)

10.38%

Current Ratio(mrq)

4.69%

Quick Ratio(mrq)

4.06%

Book Value Per Share(mrq)

11.41

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.26

Free Cash Flow(ytd)

-39.06M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement